Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.61 |
| ▸ | HTT | P42858 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | RECQL | P46063 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL524804 | 1.00 | MAPT (0.61) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL13916105 | 0.92 | MAPT (0.56) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL9533849 | 0.88 | RECQL (0.63) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL7367457 | 0.84 | MAPT (0.57) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL7367460 | 0.84 | MAPT (0.57) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL5946453 | 0.84 | MAPT (0.77) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL31531972 | 0.83 | MAPT (0.56) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL899889 | 0.83 | MAPT (0.56) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL3162509 | 0.83 | MAPT (0.56) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL6071233 | 0.82 | MAPT (0.55) | MAPTALDH1A1HTTGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111747422-B | Preparation method of ultrapure sodium silicate for silicon dioxide | 安徽龙泉硅材料有限公司 | 2023-07-28 | — | — | CN | claimed |
| US-20120028045-A1 | Processes for the Preparation of Indiplon and Intermediates Thereof | GLENMARK GENERICS LTD (IN) | 2012-02-02 | — | — | US | claimed |
| EP-1713808-B1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC (US) | 2010-02-24 | — | — | EP | claimed |
| US-7498434-B2 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC (US) | 2009-03-03 | — | — | US | claimed |
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC, (US) | 2007-07-05 | — | — | US | claimed |
| CN-111747422-B | Preparation method of ultrapure sodium silicate for silicon dioxide | 安徽龙泉硅材料有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-111747422-A | Preparation method of ultrapure sodium silicate for silicon dioxide | 安徽龙泉硅材料有限公司 | 2020-10-09 | — | — | CN | disclosed |
| US-20120028045-A1 | Processes for the Preparation of Indiplon and Intermediates Thereof | GLENMARK GENERICS LTD (IN) | 2012-02-02 | — | — | US | disclosed |
| US-20120028045-A1 | Processes for the Preparation of Indiplon and Intermediates Thereof | GLENMARK GENERICS LTD (IN) | 2012-02-02 | — | — | US | disclosed |
| US-20120028045-A1 | Processes for the Preparation of Indiplon and Intermediates Thereof | GLENMARK GENERICS LTD (IN) | 2012-02-02 | — | — | US | disclosed |
| WO-2010109480-A2 | PROCESSES FOR THE PREPARATION OF INDIPLON AND INTERMEDIATES THEREOF | GLENMARK GENERICS LIMITED (IN) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010109480-A2 | PROCESSES FOR THE PREPARATION OF INDIPLON AND INTERMEDIATES THEREOF | GLENMARK GENERICS LIMITED (IN) | 2010-09-30 | — | — | WO | disclosed |
| US-6399621-B1 | SEDATIVE, HYPNOTIC, ANXIOLYTIC, ANTICONVULSANT, AND SKELETAL MUSCLE RELAXANT AGENT | AMERICAN CYANAMID COMPANY | 2002-06-04 | — | — | US | disclosed |
| US-5219857-A | Method of treating cognitive and related neural behavioral problems | AMERICAN CYANAMID COMPANY (US) | 1993-06-15 | — | — | US | disclosed |
| US-5126340-A | Antidepressants | AMERICAN CYANAMID COMPANY (US) | 1992-06-30 | — | — | US | disclosed |
| US-4963553-A | TREATING COGNITIVE AND NEURAL BEHAVIORAL PROBLEMS IN MAMMALS | AMERICAN CYANAMID CO. (US) | 1990-10-16 | — | — | US | disclosed |
| US-4847256-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0264773-A1 | 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1988-04-27 | — | — | EP | disclosed |
| US-4521422-A | ANTICONVULSANT, ANTIEPILEPTIC AGENTS, SEDATIVES, MUSCLE RELAXANTS | AMERICAN CYANAMID COMPANY (US) | 1985-06-04 | — | — | US | disclosed |
| EP-0129847-A2 | Aryl and heteroaryl[7-(aryl and heteroaryl)-pyrazolo-[1,5-a]-pyrimidin-3-yl]methanones | AMERICAN CYANAMID COMPANY (US) | 1985-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028045-A1 | Processes for the Preparation of Indiplon and Intermediates Thereof | CYP2D6, HLA-B, HLA-DRB1 | MAPT 4124/4885ALDH1A1 406/4885HTT 748/4885 |
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | AZI2, CDK2, TPMT | MAPT 1611/4885ALDH1A1 1128/4885HTT 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.